Bill Name: Senate Bill 282 (SB 282)

Primary Sponsor: Sen. Ed Charbonneau

Status: 02/23/2026  - Second reading: amended, ordered engrossed

AmSpa’s Take: There has been a growing national trend to regulate and license medical spas and aesthetic practices. This bill takes a unique approach and places enforcement under the pharmacy board. Compounding has been a hot button issue recently as well. Most existing compound regulations are focused on pharmacy practices. This one would regulate physician in-office compounding as well. 

UPDATE: On 01/21/2026 the Senate Health and Provider Services Committee, without a public hearing or comment period, adopted several amendments to SB 282 and voted unanimously to recommend it be passed by the Senate. The updated version is available at this link (warning PDF). The changes from the initial version are as follows:

The section on compounding now only applies to compounding glucagon-like-peptide-1s (GLP-1), like semaglutide and tirzepatide, when used for weight management. Hospitals and category II pharmacies are exempted from these requirements. SB 282 also exempts compounding of GLP-1s when it is for a specific individual due to an allergy or specific dosage specification requirement. Additionally, the documentation requirements for using the bulk drug substances when compounding GLP-1s have been significantly expanded as shown beginning on page 3 of the bill linked above. 

The section on medical spa registration has also become significantly more complex. Now as part of applying for the registration medical spas must list all health care services and medications they intend to provide at the medical spa. This includes designating whether any of the prescription drugs are compounded. In addition to designating their responsible practitioner they must now list all persons operating in the medical spa as well as their license information. Medical spas that fail to register can be subject to a $5,000 fine and be required to register. 

The amendment also replaces the term “responsible person” with “responsible practitioner.” This resolves an ambiguity in the initial bill on what qualifications were needed for this role. This practitioner must be a physician, an advanced practice nurse, or a physician assistant who have prescriptive authority and have education and training in the medical services and the medications used at the medical spa. The responsible practitioner is also required to ensure that each person working at the medical spa is licensed and trained to provide the services. 

In all the medical spa registration requirements have become much more complicated and burdensome and would require continuous updating of the registration based on services, medications, and the practitioners employed by the medical spa. The compounding section has become narrower, excluding most types of compounding, but focusing exclusively on GLP-1 compounding. But with this narrowing scope the requirements to engage in this type of compounding have become significantly more complex. As the bill has left the committee with a recommendation to pass, the next step will be a vote by the senate as a whole. The bill hasn’t yet been placed on the senate calendar for vote so there is time to contact your state senator to provide comment or feedback.

Analysis: Currently in Indiana, as in most states, medical spas are regulated the same as other medical practices. Similarly, existing compounding rules are primarily directed at regulating the practice of pharmacies and not medical practices. If passed, SB 282 would create licensing and practice requirements for medical spas and would increase regulation of compounding, including physician in-office compounding.

Under SB 282, a medical spa is defined to mean a facility or practice that offers medical services and that prepares, administers, or dispenses medication offering to provide cosmetic or lifestyle treatments including weight loss, wellness, longevity, or cosmetic or aesthetic health services. Facilities that hold a different state license are exempt from this definition. If passed, SB 282 would require that, starting January 1, 2027, all medical spas would need to apply for a registration as a medical spa. Failure to register can result in fines or being prohibited to do business in Indiana. Medical spas are required to report all serious adverse events to the pharmacy board. The board is empowered to inspect medical spas and investigate violations. The information for registered medical spas would be included in a public database. 

As part of obtaining a registration, every medical spa must denote a “responsible person.” Under the current language, a responsible person must be physically present on site for enough time to ensure that the medical spa is complying with the requirements. Oddly, SB 282 doesn’t require that the responsible person hold a specific license. As part of the application, the responsible person’s license number must be included. But the rest of the bill doesn’t say what they need to be licensed as: physician, pharmacist, nurse practitioner, physician assistant, etc. It is likely that this bill will be amended to define which licenses qualify. Board approval may be needed for a responsible person to oversee more than one location. 

The proposed compounding rules are technical but apply to both pharmacist and physicians, as well as individuals supervised by them. These persons would be prohibited from compounding unless they: 

1. Use a bulk drug substance that has a monograph, is part of a Food and Drug Administration (FDA) approved drug or appears on an FDA bulk drug substance list;
2. The bulk drug substance has been reviewed as part of a new drug application and approved by the FDA;
3. The substance is pharmaceutical grade;
4. The substance has a certificate of analysis as to its contents, county of manufacture, and list of impurities;
5. The substance has undergone quality control testing;
6. The substance has a written verification that it was manufactured in an FDA registered establishment which has been inspected in the last 2 years and passed for good manufacturing practices; and
7. The compounding complies with FDA rules. 

SB 282 would also require facilities to keep records as to the process and to produce these records within one day of request. These rules would likely impact the compounding of popular medications such as peptides and GLP-1 medications. 

Most bills that seek to regulate medical spas are usually under the responsibility of the medical board. This one is somewhat unusual in placing enforcement and oversight with the pharmacy board. Of note, a very similar bill has been introduced in Florida. If you would like additional information, to read the language of this bill or to contact the sponsors or committee, you can find the information you need through this link: SB 282.